Cyclopharm Limited

Equities

CYC

AU000000CYC5

Advanced Medical Equipment & Technology

Market Closed - Australian S.E. Other stock markets 01:55:00 2024-06-03 am EDT			5-day change	1st Jan Change
1.42 ^AUD	-1.05%		-13.94%	-26.23%

May. 27	Cyclopharm Raises AU$20 Million Share Placement for Technegas Commercialization; Shares Down 16%	MT
May. 24	Cyclopharm to Raise AU$20 Million via Placement, AU$2 Million via Share Purchase Plan	MT

Cyclopharm Limited Provides Unaudited Revenue Guidance for the Full Year 2020

January 13, 2021 at 09:44 pm EST

Cyclopharm Limited provided unaudited revenue guidance for the full year 2020. The company to report that in an unprecedented and challenging year with revenues impacted by COVID19, sales have rebounded in the second half with total full year 2020 revenue expected to be in line with that of full year 2019 at approximately AUD 14 million.

Latest news about Cyclopharm Limited

Cyclopharm Raises AU$20 Million Share Placement for Technegas Commercialization; Shares Down 16%	May. 27	MT
Cyclopharm to Raise AU$20 Million via Placement, AU$2 Million via Share Purchase Plan	May. 23	MT
Cyclopharm's Technegas Device Carries Out Imaging of First US Patients	Mar. 19	MT
Cyclopharm Limited(ASX:CYC) added to S&P/ASX All Ordinaries Index	Mar. 17	CI
Cyclopharm Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Cyclopharm Limited Appoints John Wigglesworth to its Board as Non- Executive Director	Feb. 18	CI
Cyclopharm Appoints CFO; Shares Rise 3%	Feb. 12	MT
Cyclopharm Signs First US Deal for Inhalable Imaging Product	Dec. 05	MT
Argenica Therapeutics Appoints Nonexecutive Chair	Nov. 29	MT
Cyclopharm Advances Rollout of Imaging Drug in the US	Nov. 15	MT
Cyclopharm Says U.S. SNMMI Confirms FDA Nod for Technegas	23-10-04	MT
Cyclopharm Secures US FDA Clearance for Inhalable Imaging Product; Shares Rise 5%	23-10-02	MT
Cyclopharm Limited Declares Unfranked Interim Dividend for the Six Months Ended June 30, 2023, Payable on 11 September 2023	23-08-21	CI
Cyclopharm Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-21	CI
US FDA Completes Site Inspection for Cyclopharm’s Technegas Facility	23-08-08	MT
Australian Shares Retreat Ahead of Federal Budget	23-05-09	MT
Cyclopharm Secures US FDA Inspection Date for Imaging Drug Production Facility; Shares Rise 4%	23-05-09	MT
US FDA Confirms Receipt of Cyclopharm's Response Submission for Inhalable Imaging Agent	23-04-24	MT
Cyclopharm Takes Over Denmark-based DuPharma ApS	23-04-19	MT
Cyclopharm Limited acquired Dupharma Aps.	23-04-19	CI
Cyclopharm Limited announced that it expects to receive AUD 0.218 million in funding	23-04-16	CI
Cyclopharm Files Formal Reply to US FDA for Inhalable Imaging Agent	23-03-30	MT
Cyclopharm Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-19	CI
Cyclopharm Limited Announces Dividend for A Period of Six Months Ended December 31, 2022, Payable on April 4 2023	23-02-19	CI
Cyclopharm Receives $1.1 Million R&D Tax Rebate	22-11-29	MT

Chart Cyclopharm Limited

Duration

Period

More charts

Company Profile

Cyclopharm Limited is an Australia-based radiopharmaceutical company. The Company's principal activity is engaged in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development and distribution of third-party products to the diagnostic imaging sector. Its segments include Technegas and Molecular Imaging. The Technegas segment is a supplier of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and a distributor of products to the diagnostic imaging sector. The Molecular Imaging segment produces radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders and cardiac disease. The Company uses Technegas technology, which is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using driedTechnetium-99m in a carbon crucible. The Company distributes its products in approximately 65 countries.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-08-20 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Cyclopharm Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.9428 USD

Average target price

2.884 USD

Spread / Average Target

+205.83%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
CYCLOPHARM LIMITED	-26.23%	101M
THERMO FISHER SCIENTIFIC	+6.35%	217B
DANAHER CORPORATION	+11.82%	190B
INTUITIVE SURGICAL, INC.	+18.75%	143B
BOSTON SCIENTIFIC CORPORATION	+29.79%	111B
SIEMENS HEALTHINEERS AG	+0.65%	64.59B
EDWARDS LIFESCIENCES CORPORATION	+14.81%	52.36B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+2.06%	48.45B
AGILENT TECHNOLOGIES, INC.	-5.21%	38.03B
GE HEALTHCARE TECHNOLOGIES INC.	-0.76%	35.6B

Other Advanced Medical Equipment & Technology